Company
Headquarters: Seoul, South Korea
Employees: 2,155
CEO: Mr. Jong-Soo Woo Ph.D.
₩3.252 Trillion
KRW as of Jan. 1, 2025
US$2.21 Billion
Company | Market Cap (USD) |
---|---|
Lilly | $689.42 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $487.54 B |
Johnson & Johnson | $353.05 B |
AbbVie | $301.60 B |
Hanmi Pharm. Co., Ltd. operates as a pharmaceutical company worldwide. It develops treatments for diabetes, obesity, cancer, autoimmune, and rare diseases. The company was founded in 1973 and is based in Seoul, South Korea.
Last Financial Reports Date | Sept. 30, 2024 |
Revenue TTM | ₩1.569 T |
EBITDA | ₩492.73 B |
Gross Profit TTM | ₩829.25 B |
Profit Margin | 11.75% |
Operating Margin | 15.37% |
Quarterly Revenue Growth | 10.30% |
Hanmi Pharm. Co. Ltd has the following listings and related stock indices.
Stock: KRX: 128940 wb_incandescent